Nantahala Capital Management LLC raised its position in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 45.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,436,047 shares of the company's stock after acquiring an additional 450,413 shares during the period. Nantahala Capital Management LLC owned approximately 2.27% of ABIVAX Société Anonyme worth $10,512,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. ADAR1 Capital Management LLC lifted its holdings in ABIVAX Société Anonyme by 190.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock valued at $11,078,000 after acquiring an additional 991,781 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth $5,336,000. Boothbay Fund Management LLC purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $2,979,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $1,520,000. Finally, Franklin Resources Inc. boosted its holdings in ABIVAX Société Anonyme by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock worth $10,732,000 after buying an additional 141,710 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have weighed in on ABVX shares. JMP Securities reissued a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Wednesday. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $34.00.
Check Out Our Latest Research Report on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
ABIVAX Société Anonyme stock traded down $0.21 during midday trading on Thursday, hitting $6.91. 100,216 shares of the company were exchanged, compared to its average volume of 131,879. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $15.10. The company's fifty day moving average price is $6.61 and its 200-day moving average price is $7.58.
About ABIVAX Société Anonyme
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Recommended Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
